{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:38:01Z","timestamp":1791333481610,"version":"4.3.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40259-025-00726-0","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:50:15Z","timestamp":1749192615000},"page":"607-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Use of Biologics for Thyroid Eye Disease"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-3033","authenticated-orcid":false,"given":"Shoaib","family":"Ugradar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuil","family":"Parunakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0606","author":"TJ Smith","year":"2025","unstructured":"Smith TJ. Controversies surrounding IGF-I receptor involvement in thyroid-associated ophthalmopathy. Thyroid. 2025. https:\/\/doi.org\/10.1089\/thy.2024.0606.","journal-title":"Thyroid"},{"key":"726_CR2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3873","author":"ML Tanda","year":"2013","unstructured":"Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013. https:\/\/doi.org\/10.1210\/jc.2012-3873.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/J.AMJMED.2011.03.001","volume":"124","author":"GJ Kahaly","year":"2011","unstructured":"Kahaly GJ, Grebe SKG, Lupo MA, et al. Graves\u2019 disease: diagnostic and therapeutic challenges (multimedia activity). Am J Med. 2011;124:S2-3. https:\/\/doi.org\/10.1016\/J.AMJMED.2011.03.001.","journal-title":"Am J Med"},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/J.AJO.2006.02.047","volume":"142","author":"JA Garrity","year":"2006","unstructured":"Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142:147. https:\/\/doi.org\/10.1016\/J.AJO.2006.02.047.","journal-title":"Am J Ophthalmol"},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750.Graves","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362:726\u201338. https:\/\/doi.org\/10.1056\/NEJMra0905750.Graves.","journal-title":"N Engl J Med"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/S40123-021-00385-8","volume":"10","author":"KP Cockerham","year":"2021","unstructured":"Cockerham KP, Padnick-Silver L, Stuertz N, et al. Quality of life in patients with chronic thyroid eye disease in the United States. Ophthalmol Ther. 2021;10:975\u201387. https:\/\/doi.org\/10.1007\/S40123-021-00385-8.","journal-title":"Ophthalmol Ther"},{"key":"726_CR7","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2009.0283","author":"KA Ponto","year":"2009","unstructured":"Ponto KA, Pitz S, Pfeiffer N, et al. Quality of life and occupational disability in endocrine orbitopathy. Deutsches Aerzteblatt. 2009. https:\/\/doi.org\/10.3238\/arztebl.2009.0283.","journal-title":"Deutsches Aerzteblatt"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1089\/THY.2017.0365","volume":"27","author":"C Ferl\u00f8v-Schwensen","year":"2017","unstructured":"Ferl\u00f8v-Schwensen C, Brix TH, Heged\u00fcs L. Death by suicide in Graves\u2019 disease and Graves\u2019 orbitopathy: a nationwide Danish Register study. Thyroid. 2017;27:1475\u201380. https:\/\/doi.org\/10.1089\/THY.2017.0365.","journal-title":"Thyroid"},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"1283374","DOI":"10.3389\/FENDO.2023.1283374\/FULL","volume":"14","author":"TJ Smith","year":"2023","unstructured":"Smith TJ, Heged\u00fcs L, Lesser I, et al. How patients experience thyroid eye disease. Front Endocrinol (Lausanne). 2023;14:1283374. https:\/\/doi.org\/10.3389\/FENDO.2023.1283374\/FULL.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/J.EPRAC.2022.06.003","volume":"28","author":"Y Wang","year":"2022","unstructured":"Wang Y, Padnick-Silver L, Francis-Sedlak M, et al. Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in patients in the United States. Endocr Pract. 2022;28:842\u20136. https:\/\/doi.org\/10.1016\/J.EPRAC.2022.06.003.","journal-title":"Endocr Pract"},{"key":"726_CR11","first-page":"36","volume":"6","author":"FF Rundle","year":"1957","unstructured":"Rundle FF. Management of exophthalmos and related ocular changes in Graves\u2019 disease. Metabolism. 1957;6:36\u201348.","journal-title":"Metabolism"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/IOP.0000000000001087","volume":"35","author":"S Ugradar","year":"2019","unstructured":"Ugradar S, Rootman DB. Noninflammatory thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2019;35:461\u20134. https:\/\/doi.org\/10.1097\/IOP.0000000000001087.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/IOP.0000000000001147","volume":"34","author":"JM Uddin","year":"2018","unstructured":"Uddin JM, Rubinstein T, Hamed-Azzam S. Phenotypes of thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34:S28-33.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"726_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01297-w","author":"S Ugradar","year":"2020","unstructured":"Ugradar S, Shi L, Wang Y, et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye (Basingstoke). 2020. https:\/\/doi.org\/10.1038\/s41433-020-01297-w.","journal-title":"Eye (Basingstoke)."},{"key":"726_CR15","unstructured":"Ugradar S, Douglas R. Comparison of acute and chronic thyroid eye disease: emergence of a molecular signature. Am Acad Ophthalmol. 2022."},{"key":"726_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639\u201344. https:\/\/doi.org\/10.1136\/bjo.73.8.639.","journal-title":"Br J Ophthalmol"},{"key":"726_CR17","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185:G43-67. https:\/\/doi.org\/10.1530\/EJE-21-0479.","journal-title":"Eur J Endocrinol"},{"key":"726_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1210\/JCEM-44-1-203","volume":"44","author":"SC Werner","year":"1977","unstructured":"Werner SC. Modification of the classification of the eye changes of Graves\u2019 disease: recommendations of the ad hoc committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977;44:203\u20134. https:\/\/doi.org\/10.1210\/JCEM-44-1-203.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/J.1365-2265.2001.01241.X","volume":"54","author":"CB Terwee","year":"2001","unstructured":"Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001;54:391\u20138. https:\/\/doi.org\/10.1046\/J.1365-2265.2001.01241.X.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"726_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/BJO.82.7.773","volume":"82","author":"CB Terwee","year":"1998","unstructured":"Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82:773\u20139. https:\/\/doi.org\/10.1136\/BJO.82.7.773.","journal-title":"Br J Ophthalmol"},{"key":"726_CR21","first-page":"222","volume":"75","author":"AP Weetman","year":"1989","unstructured":"Weetman AP, Cohen S, Gatter KC, et al. Immunohistochemical analysis of the retrobulbar tissues in Graves\u2019 ophthalmopathy. Clin Exp Immunol. 1989;75:222\u20137.","journal-title":"Clin Exp Immunol"},{"key":"726_CR22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2697","author":"L Van Steensel","year":"2012","unstructured":"Van Steensel L, Paridaens D, Van Meurs M, et al. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2012. https:\/\/doi.org\/10.1210\/jc.2011-2697.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1210\/jc.2009-1614","volume":"95","author":"RS Douglas","year":"2010","unstructured":"Douglas RS, Afifiyan NF, Hwang CJ, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95:430\u20138. https:\/\/doi.org\/10.1210\/jc.2009-1614.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR24","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.4049\/JIMMUNOL.178.5.3281","volume":"178","author":"RS Douglas","year":"2007","unstructured":"Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178:3281\u20137. https:\/\/doi.org\/10.4049\/JIMMUNOL.178.5.3281.","journal-title":"J Immunol"},{"key":"726_CR25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.8.5768","author":"RS Douglas","year":"2008","unstructured":"Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008. https:\/\/doi.org\/10.4049\/jimmunol.181.8.5768.","journal-title":"J Immunol"},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"E625","DOI":"10.1210\/jc.2013-3977","volume":"99","author":"B Li","year":"2014","unstructured":"Li B, Smith TJ. Regulation of IL-1 receptor antagonist by TSH in fibrocytes and orbital fibroblasts. J Clin Endocrinol Metab. 2014;99:E625\u201333. https:\/\/doi.org\/10.1210\/jc.2013-3977.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075100","author":"N Raychaudhuri","year":"2013","unstructured":"Raychaudhuri N, Fernando R, Smith TJ. Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0075100.","journal-title":"PLoS ONE"},{"key":"726_CR28","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1167\/iovs.18-23951","volume":"59","author":"Y Lu","year":"2018","unstructured":"Lu Y, Atkins SJ, Fernando R, et al. CD34: orbital fibroblasts from patients with thyroid-associated ophthalmopathy modulate TNF-\u03b1 expression in CD34 + fibroblasts and fibrocytes. Invest Ophthalmol Vis Sci. 2018;59:2615\u201322. https:\/\/doi.org\/10.1167\/iovs.18-23951.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"726_CR29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M703597200","author":"KM Hong","year":"2007","unstructured":"Hong KM, Belperio JA, Keane MP, et al. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-\u03b2 and peroxisome proliferator-activated receptor. J Biol Chem. 2007. https:\/\/doi.org\/10.1074\/jbc.M703597200.","journal-title":"J Biol Chem"},{"key":"726_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-011-0025-9","author":"J Furmaniak","year":"2012","unstructured":"Furmaniak J, Sanders J, Young S, et al. In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1\u201370). Auto Immun Highlights. 2012. https:\/\/doi.org\/10.1007\/s13317-011-0025-9.","journal-title":"Auto Immun Highlights"},{"key":"726_CR31","first-page":"543","volume":"3","author":"ED Bothun","year":"2009","unstructured":"Bothun ED, Scheurer RA, Harrison AR, et al. Update on thyroid eye disease and management. Clin Ophthalmol. 2009;3:543\u201351.","journal-title":"Clin Ophthalmol"},{"key":"726_CR32","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1614949.","journal-title":"N Engl J Med"},{"key":"726_CR33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/S40618-020-01353-Y\/FIGURES\/1","volume":"44","author":"F Nicol\u00ec","year":"2021","unstructured":"Nicol\u00ec F, Lanzolla G, Mantuano M, et al. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy. J Endocrinol Invest. 2021;44:581\u20135. https:\/\/doi.org\/10.1007\/S40618-020-01353-Y\/FIGURES\/1.","journal-title":"J Endocrinol Invest"},{"key":"726_CR34","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1210\/JC.2013-4026","volume":"99","author":"T Diana","year":"2014","unstructured":"Diana T, Brown RS, Bossowski A, et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves\u2019 disease: a multicenter study. J Clin Endocrinol Metab. 2014;99:1648\u201355. https:\/\/doi.org\/10.1210\/JC.2013-4026.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/678194","volume":"2015","author":"E Kampmann","year":"2015","unstructured":"Kampmann E, Diana T, Kanitz M, et al. Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: a prospective study. Int J Endocrinol. 2015;2015: 678194. https:\/\/doi.org\/10.1155\/2015\/678194.","journal-title":"Int J Endocrinol."},{"key":"726_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/A-1525-2070\/ID\/R2021-04-0108-0025","volume":"53","author":"M St\u00f6hr","year":"2021","unstructured":"St\u00f6hr M, Oeverhaus M, Lytton SD, et al. Predicting the course of Graves\u2019 orbitopathy using serially measured TSH-receptor autoantibodies by automated binding immunoassays and the functional bioassay. Hormone Metab Res. 2021;53:435\u201343. https:\/\/doi.org\/10.1055\/A-1525-2070\/ID\/R2021-04-0108-0025.","journal-title":"Hormone Metab Res."},{"key":"726_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/THY.2010.0123\/ASSET\/IMAGES\/LARGE\/FIGURE5.JPEG","volume":"21","author":"CJJ Van Zeijl","year":"2011","unstructured":"Van Zeijl CJJ, Fliers E, Van Koppen CJ, et al. Thyrotropin receptor-stimulating Graves\u2019 disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves\u2019 ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways. Thyroid. 2011;21:169\u201376. https:\/\/doi.org\/10.1089\/THY.2010.0123\/ASSET\/IMAGES\/LARGE\/FIGURE5.JPEG.","journal-title":"Thyroid"},{"key":"726_CR38","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-16-0008","volume":"2016","author":"A Tabasum","year":"2016","unstructured":"Tabasum A, Khan I, Taylor P, et al. Thyroid antibody-negative euthyroid Graves\u2019 ophthalmopathy. Endocrinol Diabetes Metab Case Rep. 2016;2016: 160008. https:\/\/doi.org\/10.1530\/EDM-16-0008.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"726_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/S40618-020-01380-9","volume":"44","author":"T Diana","year":"2021","unstructured":"Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves\u2019 orbitopathy. J Endocrinol Invest. 2021;44:703\u201312. https:\/\/doi.org\/10.1007\/S40618-020-01380-9.","journal-title":"J Endocrinol Invest"},{"key":"726_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/08916939309014643","volume":"16","author":"DR Weightman","year":"1993","unstructured":"Weightman DR, Perros P, Sherif IH, et al. Autoantibodies to igf-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993;16:251\u20137. https:\/\/doi.org\/10.3109\/08916939309014643.","journal-title":"Autoimmunity"},{"key":"726_CR41","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith TJ, Hoa N. Immunoglobulins from patients with Graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metabol. 2004;89:5076\u201380.","journal-title":"J Clin Endocrinol Metabol"},{"key":"726_CR42","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol. 2008;181:4397\u2013405. https:\/\/doi.org\/10.4049\/jimmunol.181.6.4397.","journal-title":"J Immunol"},{"key":"726_CR43","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med. 2011;364:1920\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1012985.","journal-title":"N Engl J Med"},{"key":"726_CR44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/S00204-014-1247-1\/METRICS","volume":"88","author":"CE Staatz","year":"2014","unstructured":"Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014;88:1351\u201389. https:\/\/doi.org\/10.1007\/S00204-014-1247-1\/METRICS.","journal-title":"Arch Toxicol"},{"key":"726_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6:287\u201398. https:\/\/doi.org\/10.1016\/S2213-8587(18)30020-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"726_CR46","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2147\/OPTH.S305717","volume":"15","author":"NQQ Xian","year":"2021","unstructured":"Xian NQQ, Alnahrawy A, Akshikar R, et al. Real-world efficacy and safety of mycophenolate mofetil in active moderate-to-sight-threatening thyroid eye disease. Clin Ophthalmol. 2021;15:1921\u201332. https:\/\/doi.org\/10.2147\/OPTH.S305717.","journal-title":"Clin Ophthalmol"},{"key":"726_CR47","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1097\/IOP.0000000000001131","volume":"34","author":"D Strianese","year":"2018","unstructured":"Strianese D. Efficacy and safety of immunosuppressive agents for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34:S56\u20139. https:\/\/doi.org\/10.1097\/IOP.0000000000001131.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"726_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1530\/ACTA.0.1220008","volume":"122","author":"P Perros","year":"1990","unstructured":"Perros P, Weightman DR, Crombie AL, et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh). 1990;122:8\u201312. https:\/\/doi.org\/10.1530\/ACTA.0.1220008.","journal-title":"Acta Endocrinol (Copenh)."},{"key":"726_CR49","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","volume":"6","author":"R Rajendram","year":"2018","unstructured":"Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 \u00d7 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:299\u2013309. https:\/\/doi.org\/10.1016\/S2213-8587(18)30021-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"726_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119\u201325. https:\/\/doi.org\/10.1016\/S0162-3109(00)00192-2.","journal-title":"Immunopharmacology"},{"key":"726_CR51","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJM198911163212002\/ASSET\/31EC2557-4345-406F-9402-239A4AD2B8AB\/ASSETS\/IMAGES\/LARGE\/NEJM198911163212002_T5.JPG","volume":"321","author":"MF Prummel","year":"1989","unstructured":"Prummel MF, Mourits MPh, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy. N Engl J Med. 1989;321:1353\u20139. https:\/\/doi.org\/10.1056\/NEJM198911163212002\/ASSET\/31EC2557-4345-406F-9402-239A4AD2B8AB\/ASSETS\/IMAGES\/LARGE\/NEJM198911163212002_T5.JPG.","journal-title":"N Engl J Med"},{"key":"726_CR52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","volume":"16","author":"G Kahaly","year":"1986","unstructured":"Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16: 415422. https:\/\/doi.org\/10.1111\/j.1365-2362.1986.tb01016.x.","journal-title":"Eur J Clin Invest"},{"key":"726_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1210\/clinem\/dgac252","volume":"107","author":"G Barbesino","year":"2022","unstructured":"Barbesino G, Salvi M, Freitag SK. Future projections in thyroid eye disease. J Clin Endocrinol Metab. 2022;107:47\u201356. https:\/\/doi.org\/10.1210\/clinem\/dgac252.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR54","doi-asserted-by":"publisher","unstructured":"Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;2014(6):CD000957. https:\/\/doi.org\/10.1002\/14651858.CD000957.PUB2\/MEDIA\/CDSR\/CD000957\/IMAGE_N\/NCD000957-CMP-002-04.PNG.","DOI":"10.1002\/14651858.CD000957.PUB2\/MEDIA\/CDSR\/CD000957\/IMAGE_N\/NCD000957-CMP-002-04.PNG"},{"key":"726_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2022.113074","volume":"150","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Hua Z, Luo X, et al. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother. 2022;150: 113074. https:\/\/doi.org\/10.1016\/J.BIOPHA.2022.113074.","journal-title":"Biomed Pharmacother"},{"key":"726_CR56","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/12890.3","volume":"2014","author":"D Strianese","year":"2014","unstructured":"Strianese D, Iuliano A, Ferrara M, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol. 2014;2014: 128903. https:\/\/doi.org\/10.1155\/2014\/12890.3.","journal-title":"J Ophthalmol"},{"key":"726_CR57","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4172\/2155-9570.1000422","volume":"6","author":"E Rivera-Grana","year":"2015","unstructured":"Rivera-Grana E, Lin P, Suhler EB, et al. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol. 2015;6:422. https:\/\/doi.org\/10.4172\/2155-9570.1000422.","journal-title":"J Clin Exp Ophthalmol."},{"key":"726_CR58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/IOP.0000000000001279","volume":"35","author":"KL Yong","year":"2019","unstructured":"Yong KL, Chng CL, Ming Sie N, et al. Methotrexate as an adjuvant in severe thyroid eye disease: does it really work as a steroid-sparing agent? Ophthalmic Plast Reconstr Surg. 2019;35:369\u201373. https:\/\/doi.org\/10.1097\/IOP.0000000000001279.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"726_CR59","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/bjo.73.8.639","volume":"73","author":"MP Mourits","year":"1989","unstructured":"Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639\u201344.","journal-title":"Br J Ophthalmol"},{"key":"726_CR60","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/JC.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422. https:\/\/doi.org\/10.1210\/JC.2014-3014.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR61","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/JC.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Leon BGC, et al. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100:432. https:\/\/doi.org\/10.1210\/JC.2014-2572.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR62","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan MN, Salvi M. Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy: lessons from randomized control trials. Eur J Endocrinol. 2017;176:R101\u20139. https:\/\/doi.org\/10.1530\/EJE-16-0552.","journal-title":"Eur J Endocrinol"},{"key":"726_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s42000-021-00282-6","volume":"20","author":"J Chen","year":"2021","unstructured":"Chen J, Chen G, Sun H. Intravenous rituximab therapy for active Graves\u2019 ophthalmopathy: a meta-analysis. Hormones. 2021;20:279\u201386. https:\/\/doi.org\/10.1007\/s42000-021-00282-6.","journal-title":"Hormones"},{"key":"726_CR64","doi-asserted-by":"publisher","unstructured":"Burch TFMHB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022. https:\/\/doi.org\/10.1089\/THY.2022.0251.","DOI":"10.1089\/THY.2022.0251"},{"key":"726_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/08916939708996275","volume":"25","author":"I Moln\u00e1r","year":"2009","unstructured":"Moln\u00e1r I, Bal\u00e1zs C. High circulating IL-6 level in Graves\u2019 ophthalmopathy. Autoimmunity. 2009;25:91\u20136. https:\/\/doi.org\/10.3109\/08916939708996275.","journal-title":"Autoimmunity"},{"key":"726_CR66","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV P\u00e9rez-Moreiras","year":"2014","unstructured":"P\u00e9rez-Moreiras JV, \u00c1lvarez-L\u00f3pez A, G\u00f3mez EC. Treatment of active corticosteroid-resistant graves\u2019 orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30:162\u20137. https:\/\/doi.org\/10.1097\/IOP.0000000000000037.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"726_CR67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u201390. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038.","journal-title":"Am J Ophthalmol"},{"key":"726_CR68","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3390\/jcm9092816","volume":"9","author":"L S\u00e1nchez-Bilbao","year":"2020","unstructured":"S\u00e1nchez-Bilbao L, Mart\u00ednez-L\u00f3pez D, Revenga M, et al. Anti-IL-6 receptor tocilizumab in refractory Graves\u2019 orbitopathy: national multicenter observational study of 48 patients. J Clin Med. 2020;9:2816. https:\/\/doi.org\/10.3390\/jcm9092816.","journal-title":"J Clin Med"},{"key":"726_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2025.2452181\/ASSET\/A51E300E-A3C4-47EC-8ADC-1D745BFEE958\/ASSETS\/GRAPHIC\/IORB_A_2452181_F0001_B.GIF","author":"K Farde","year":"2025","unstructured":"Farde K, Tr\u00e4isk F. Tocilizumab: a disease-modulating treatment for thyroid associated ophthalmopathy? Orbit. 2025. https:\/\/doi.org\/10.1080\/01676830.2025.2452181\/ASSET\/A51E300E-A3C4-47EC-8ADC-1D745BFEE958\/ASSETS\/GRAPHIC\/IORB_A_2452181_F0001_B.GIF.","journal-title":"Orbit"},{"key":"726_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/J.BEEM.2022.101620","volume":"37","author":"ACH Lee","year":"2023","unstructured":"Lee ACH, Kahaly GJ. Pathophysiology of thyroid-associated orbitopathy. Best Pract Res Clin Endocrinol Metab. 2023;37: 101620. https:\/\/doi.org\/10.1016\/J.BEEM.2022.101620.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"726_CR71","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/S40618-022-01862-Y","volume":"45","author":"G Lanzolla","year":"2022","unstructured":"Lanzolla G, Maglionico MN, Comi S, et al. Sirolimus as a second-line treatment for Graves\u2019 orbitopathy. J Endocrinol Invest. 2022;45:2171\u201380. https:\/\/doi.org\/10.1007\/S40618-022-01862-Y.","journal-title":"J Endocrinol Invest"},{"key":"726_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/J.BEEM.2020.101383","volume":"34","author":"TJ Smith","year":"2020","unstructured":"Smith TJ. Thyroid-associated ophthalmopathy: emergence of teprotumumab as a promising medical therapy. Best Pract Res Clin Endocrinol Metab. 2020;34: 101383. https:\/\/doi.org\/10.1016\/J.BEEM.2020.101383.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"726_CR73","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","volume":"33","author":"RS Douglas","year":"2019","unstructured":"Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye (Basingstoke). 2019;33:183\u201390. https:\/\/doi.org\/10.1038\/s41433-018-0321-y.","journal-title":"Eye (Basingstoke)."},{"key":"726_CR74","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1910434.","journal-title":"N Engl J Med"},{"key":"726_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317806","author":"AP Jain","year":"2020","unstructured":"Jain AP, Gellada N, Ugradar S, et al. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol. 2020. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317806.","journal-title":"Br J Ophthalmol"},{"key":"726_CR76","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X Study. Ophthalmology. 2022;129:438\u201349. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017.","journal-title":"Ophthalmology"},{"key":"726_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2025.101464","author":"Y Hiromatsu","year":"2025","unstructured":"Hiromatsu Y, Ishikawa E, Kozaki A, et al. A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. Lancet Reg Health West Pac. 2025. https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101464.","journal-title":"Lancet Reg Health West Pac."},{"key":"726_CR78","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/CLINEM\/DGAD637","volume":"109","author":"RS Douglas","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023;109:25\u201335. https:\/\/doi.org\/10.1210\/CLINEM\/DGAD637.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR79","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAC627","author":"L Amarikwa","year":"2022","unstructured":"Amarikwa L, Mohamed A, Kim SH, et al. Teprotumumab-related hyperglycemia. J Clin Endocrinol Metab. 2022. https:\/\/doi.org\/10.1210\/CLINEM\/DGAC627.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR80","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021;9:360\u201372. https:\/\/doi.org\/10.1016\/S2213-8587(21)00056-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"726_CR81","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1210\/CLINEM\/DGAC627","volume":"108","author":"L Amarikwa","year":"2023","unstructured":"Amarikwa L, Mohamed A, Kim SH, et al. Teprotumumab-related hyperglycemia. J Clin Endocrinol Metab. 2023;108:858\u201364. https:\/\/doi.org\/10.1210\/CLINEM\/DGAC627.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR82","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/thy.2023.0466","volume":"34","author":"RS Douglas","year":"2024","unstructured":"Douglas RS, Parunakian E, Tolentino J, et al. A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease. Thyroid. 2024;34:134\u20137. https:\/\/doi.org\/10.1089\/thy.2023.0466.","journal-title":"Thyroid"},{"key":"726_CR83","doi-asserted-by":"publisher","DOI":"10.1089\/THY.2023.0466","author":"RS Douglas","year":"2023","unstructured":"Douglas RS, Parunakian E, Tolentino J, et al. A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease. Thyroid. 2023. https:\/\/doi.org\/10.1089\/THY.2023.0466.","journal-title":"Thyroid"},{"key":"726_CR84","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/MOO.0000000000000652","volume":"28","author":"L Gao","year":"2020","unstructured":"Gao L, Nakagawa T. Insulin-like growth factor 1: role in the auditory system and therapeutic potential in otology. Curr Opin Otolaryngol Head Neck Surg. 2020;28:286\u201390. https:\/\/doi.org\/10.1097\/MOO.0000000000000652.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"726_CR85","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/S41574-024-00995-9","volume":"20","author":"JA Brant","year":"2024","unstructured":"Brant JA, Kikkawa DO, Smith TJ. Hearing abnormalities in patients treated with teprotumumab. Nat Rev Endocrinol. 2024;20:381\u20132. https:\/\/doi.org\/10.1038\/S41574-024-00995-9.","journal-title":"Nat Rev Endocrinol"},{"key":"726_CR86","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/J.EPRAC.2024.08.005","volume":"30","author":"TD Hoang","year":"2024","unstructured":"Hoang TD, Flor RJ, De La Torre S, et al. Effects of teprotumumab and role of human leukocyte antigens markers in patients with thyroid eye disease. Endocr Pract. 2024;30:1038\u201343. https:\/\/doi.org\/10.1016\/J.EPRAC.2024.08.005.","journal-title":"Endocr Pract"},{"key":"726_CR87","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","volume":"263","author":"CJ Hwang","year":"2024","unstructured":"Hwang CJ, Rebollo NP, Mechels KB, et al. Reactivation after teprotumumab treatment for active thyroid eye disease. Am J Ophthalmol. 2024;263:152\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001.","journal-title":"Am J Ophthalmol"},{"key":"726_CR88","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ophtha.2024.07.018","volume":"132","author":"S Ugradar","year":"2025","unstructured":"Ugradar S, Parunakian E, Malkhasyan E, et al. The rate of re-treatment in patients treated with teprotumumab. Ophthalmology. 2025;132:92\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2024.07.018.","journal-title":"Ophthalmology"},{"key":"726_CR89","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000002280","author":"Y Chen","year":"2025","unstructured":"Chen Y, Linaburg T, Wang S, et al. Observational characterization of the retreatment course of patients with thyroid eye disease. J Neuroophthalmol. 2025. https:\/\/doi.org\/10.1097\/WNO.0000000000002280.","journal-title":"J Neuroophthalmol"},{"key":"726_CR90","unstructured":"Viridian Therapeutics, Inc. Viridian Therapeutics announces positive topline results from veligrotug phase 3 THRIVE-2 clinical trial in patients with chronic thyroid eye disease. https:\/\/investors.viridiantherapeutics.com\/news\/news-details\/2024\/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Veligrotug-Phase-3-THRIVE-2-Clinical-Trial-in-Patients-with-Chronic-Thyroid-Eye-Disease\/default.aspx. Accessed 1 May 2025."},{"key":"726_CR91","unstructured":"Ugradar S, Kossler A, Turbin RE, Cockerham K, Nijhawan N, Tang R, et al. MRI\/CT analysis shows potential for disease-modifying effects of VRDN-001, a targeted TED therapy: reduced proptosis and muscle\/fat volume in a proof-of-concept study in active TED. European Society of Ophthalmic Plastic Reconstructive Surgeons. 2024."},{"key":"726_CR92","unstructured":"Sling Therapeutics. Sling Therapeutics announces positive topline results from phase 2b\/3 LIDS clinical trial of oral small molecule linsitinib in patients with thyroid eye disease. https:\/\/www.slingtx.com\/2025\/01\/14\/sling-therapeutics-announces-positive-topline-results-from-phase-2b-3-lids-clinical-trial-of-oral-small-molecule-linsitinib-in-patients-with-thyroid-eye-disease\/. Accessed 1 Apr 2025."},{"key":"726_CR93","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/NRI2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715\u201325. https:\/\/doi.org\/10.1038\/NRI2155.","journal-title":"Nat Rev Immunol"},{"key":"726_CR94","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1210\/CLINEM\/DGAD381","volume":"108","author":"GJ Kahaly","year":"2023","unstructured":"Kahaly GJ, Dolman PJ, Wolf J, et al. Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab. 2023;108:3122\u201334. https:\/\/doi.org\/10.1210\/CLINEM\/DGAD381.","journal-title":"J Clin Endocrinol Metab"},{"key":"726_CR95","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/AJH.27487","volume":"99","author":"JW Jacobs","year":"2024","unstructured":"Jacobs JW, Booth GS, Raza S, et al. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. Am J Hematol. 2024;99:2351\u201366. https:\/\/doi.org\/10.1002\/AJH.27487.","journal-title":"Am J Hematol"},{"key":"726_CR96","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/S40263-024-01090-3\/TABLES\/5","volume":"38","author":"N Alfaidi","year":"2024","unstructured":"Alfaidi N, Karmastaji S, Matic A, et al. FcRn inhibitor therapies in neurologic diseases. CNS Drugs. 2024;38:425\u201341. https:\/\/doi.org\/10.1007\/S40263-024-01090-3\/TABLES\/5.","journal-title":"CNS Drugs"},{"key":"726_CR97","doi-asserted-by":"publisher","DOI":"10.1530\/ENDOABS.92.PS1-10-01","author":"J Swaney","year":"2023","unstructured":"Swaney J, Jun T, Elliott E, et al. Targeting interleukin-11 signaling, an emerging patholgical mediator in thyroid eye disease. Endocr Abstr. 2023. https:\/\/doi.org\/10.1530\/ENDOABS.92.PS1-10-01.","journal-title":"Endocr Abstr"},{"key":"726_CR98","unstructured":"Shah SA, Lu T, Yu M, et al. Comparison of treatment cost and quality-of-life impact of thyroid eye disease therapies. Invest Ophthalmol Vis Sci. 2022;63:4002-A0344-4002-A0344."},{"key":"726_CR99","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0189","volume":"11","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022;11: e220189. https:\/\/doi.org\/10.1530\/ETJ-22-0189.","journal-title":"Eur Thyroid J."},{"key":"726_CR100","unstructured":"Amgen. Tepezza\u00ae (teprotumumab) received approval in Japan for the treatment of active thyroid eye disease. https:\/\/www.amgen.com\/newsroom\/press-releases\/2024\/09\/tepezza-teprotumumab-receives-approval-in-japan-for-the-treatment-of-active-thyroid-eye-disease. 2024. Accessed 30 Mar 2025."},{"key":"726_CR101","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Summary of opinion (initial authorisation), Tepezza (teprotumumab). 2025. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-tepezza_en.pdf. Accessed 1 May 2025."},{"key":"726_CR102","doi-asserted-by":"publisher","first-page":"A843","DOI":"10.1210\/JENDSO\/BVAB048.1720","volume":"5","author":"G Singh","year":"2021","unstructured":"Singh G, Sehgal M, Mithal A, et al. Severe thyroid eye disease in the US: a national perspective. J Endocr Soc. 2021;5:A843. https:\/\/doi.org\/10.1210\/JENDSO\/BVAB048.1720.","journal-title":"J Endocr Soc."},{"key":"726_CR103","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002839","author":"HL Walsh","year":"2024","unstructured":"Walsh HL, Clauss KD, Meyer BI, et al. Surgical timing for patients with thyroid eye disease treated with teprotumumab: a collaborative multicenter study. Ophthalmic Plast Reconstr Surg. 2024. https:\/\/doi.org\/10.1097\/IOP.0000000000002839.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"726_CR104","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/J.JCJO.2024.06.003","volume":"60","author":"NJ Topilow","year":"2025","unstructured":"Topilow NJ, Penteado RC, Ting M, et al. Orbital decompression following treatment with teprotumumab for thyroid eye disease. Can J Ophthalmol. 2025;60:e59-64. https:\/\/doi.org\/10.1016\/J.JCJO.2024.06.003.","journal-title":"Can J Ophthalmol"},{"key":"726_CR105","doi-asserted-by":"publisher","DOI":"10.1210\/ENDREV\/BNAE018","author":"S Ugradar","year":"2024","unstructured":"Ugradar S, Malkhasyan E, Douglas RS. Teprotumumab for the treatment of thyroid eye disease. Endocr Rev. 2024. https:\/\/doi.org\/10.1210\/ENDREV\/BNAE018.","journal-title":"Endocr Rev"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00726-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00726-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00726-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:03:43Z","timestamp":1750676623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00726-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00726-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"5 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Shoaib Ugradar is a prior consultant for Horizon Therapeutics, Viridian Therapeutics, and Acelyrin. Raymond S. Douglas is a prior consultant for Horizon Therapeutics, Immunovant Corporation, and Viridian Therapeutics. He is currently an employee of Sling Therapeutics. Emanuil Parunakian has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SU and EP conducted the literature search. All authors contributed to the writing and editing of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}